{
    "medicine_id": "f18258450d5bc6c31e0683f9a732bec5831e251f",
    "platform_id": "DB06042",
    "metadata": {
        "name": "Reagila 1 5 mg Capsule",
        "composition": "1 5 mg ZEN 012",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in cancer tumors unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In vitro ZEN 012 has shown potent in vitro anti proliferative activity at nanomolar concentrations against human tumor cell lines of different origin ZEN 012 is active in tumor cell lines which are resistant to cisplatin and doxorubicin as well as to tubulin inhibitors such as vincristine and paclitaxel Furthermore it was shown thatZEN 012 is a catalytic inhibitor of the enzyme topoisomerase II with the same potency as amsacrine In vivo Given orally once or twice weekly ZEN 012 proved to be a potent inhibitor of in vivo tumor growth in mammary lung renal colon melanoma xenograft models as well as in leukemia cancer models at well tolerated doses 16 40mg kg Furthermore ZEN 012 showed good safety and toxicity profiles in a series of rodent and non rodent studies",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}